Quanterix expands licensing agreement with ALZpath for pTau217 antibody

Source excerpt

ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research News provided by ALZpath, Inc. Oct 07, 2026, 08:30 ET Share this article Share to X Share this article Share to X Expanded Broadens Use of ALZpath's Proprietary pTau217 Antibody Technology Across the Quanterix Simoa® Research Portfolio CARLSBAD, Calif. , Oct. 7, 2026 /PRNewswire/ -- ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology. The expanded agreement builds on the original 2023 agreement when Quanterix selected ALZpath's antibody to create the Simoa® ALZpath pTau217 Assay for use on Quanterix's Simoa® platform. The assay has since been used extensively in neurodegenerative disease research, appearing in 161 peer-reviewed publications. In December 2025, a landmark population study published in Nature used the Simoa® ALZpath pTau217 Assay to demonstrate the value of deploying pTau217 blood tests at scale and their

Company press release